This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Albino, A. P. Articles by Darzynkiewicz, Z. Search for Related Content PubMed PubMed Citation Articles by Albino, A. P. Articles by Darzynkiewicz, Z.

Cell Cycle Arrest and Apoptosis of Melanoma Cells by Docosahexaenoic Acid: Association with Decreased pRb Phosphorylation¹

The American Health Foundation [A. P. A., L. R., J. C., D. P. R.] and Brander Cancer Research Institute at The New York Medical College [G. J., F. T., Z. D.], Valhalla, New York 10595

The incidence of cutaneous malignant melanoma is undergoing a dramatic increase in persons with light-color skin in all parts of the world. The prognosis for individuals with advanced disease is dismal due to the lack of effective treatment options. Thus, there is a need for new approaches to control tumor progression. Epidemiological, experimental, and mechanistic data implicate -6 polyunsaturated fatty acids (PUFAs) as stimulators and long-chain -3 PUFAs as inhibitors of development and progression of a range of human cancers, including melanoma. The aim of this study was to assess the mechanisms by which docosahexaenoic acid (DHA), an -3 PUFA, affects human melanoma cells.

Exponentially growing melanoma cell lines were exposed in vitro to DHA and then assessed for (a) inhibition of cell growth; (b) expression of cyclins and cyclin-dependent kinase inhibitors in individual cells by flow cytometry and immunocytochemistry using specific monoclonal antibodies to cyclin D1, cyclin E, p21^WAF1/CIP1, or p27^KIP1; and (c) expression of total pRb^T independent of phosphorylation state and hypophosphorylated pRb^P- in fixed cells by flow cytometry and immunocytochemistry using specific monoclonal antibodies to pRb^T or pRb^P-, respectively. After treatment with increasing concentrations of DHA, cell growth in a majority of melanoma cell lines (7 of 12) was inhibited, whereas in 5 of 12 cell lines, cell growth was minimally affected. Two melanoma cell lines were examined in detail, one resistant (SK-Mel-29) and one sensitive (SK-Mel-110) to the inhibitory activity of DHA. SK-Mel-29 cells were unaffected by treatment with up to 2 µg/ml DHA whether grown in the absence or presence of 1% fetal bovine serum (FBS). No appreciable change was observed in cell growth, cell cycle distribution, the status of pRb phosphorylation, cyclin D1 expression, or the levels of the cyclin-dependent kinase inhibitors p21 and p27. In contrast, SK-Mel-110 cell growth was inhibited by DHA with the cells accumulating either in G₁ or S phase: 0% in SK-Mel-29 versus 13.3 or 41.2% in SK-Mel-110 in the absence or presence of FBS, respectively. In the absence of serum, considerable death occurred by apoptosis. In addition, DHA treatment resulted in increasing numbers of SK-Mel-110 cells (from 12 to >40%) expressing hypophosphorylated pRb, whereas the levels of cyclin D1 and p21 changed little. Expression of p27 in these cells increased >2.5 times when grown in the absence of FBS but not in the presence of 1% FBS.

Thus, we show for the first time that DHA inhibits the growth of cultured metastatic melanoma cells. Furthermore, growth inhibition correlates with a quantitative increase in hypophosphorylated pRb in the representative sensitive melanoma cell line SK-Mel-110. Although multiple factors influence pRb phosphorylation, it appears that both cyclin D1 and p21 expression do not change in the presence of DHA, although p27 was strikingly increased in SK-Mel-110 cells in the absence of FBS. The fact that pRb became hypophosphorylated after exposure to DHA suggests a cross-talk mechanism between fatty acid metabolism and the pRb pathway. Determining the mechanism by which PUFAs can inhibit melanoma growth will be an important first step in the rational use of PUFAs as antitumor agents.

This article has been cited by other articles:

				N. A. Khan, K. Nishimura, V. Aires, T. Yamashita, D. Oaxaca-Castillo, K. Kashiwagi, and K. Igarashi Docosahexaenoic acid inhibits cancer cell growth via p27Kip1, CDK2, ERK1/ERK2, and retinoblastoma phosphorylation J. Lipid Res., October 1, 2006; 47(10): 2306 - 2313. [Abstract] [Full Text] [PDF]

				D. Winston Herbal Therapy Integr Cancer Ther, September 1, 2005; 4(3): 258 - 261. [PDF]

				L. A. Sauer, R. T. Dauchy, D. E. Blask, J. A. Krause, L. K. Davidson, and E. M. Dauchy Eicosapentaenoic Acid Suppresses Cell Proliferation in MCF-7 Human Breast Cancer Xenografts in Nude Rats via a Pertussis Toxin-Sensitive Signal Transduction Pathway J. Nutr., September 1, 2005; 135(9): 2124 - 2129. [Abstract] [Full Text] [PDF]

				L. A. Sauer, R. T. Dauchy, D. E. Blask, J. A. Krause, L. K. Davidson, E. M. Dauchy, K. J. Welham, and K. Coupland Conjugated Linoleic Acid Isomers and Trans Fatty Acids Inhibit Fatty Acid Transport in Hepatoma 7288CTC and Inguinal Fat Pads in Buffalo Rats J. Nutr., August 1, 2004; 134(8): 1989 - 1997. [Abstract] [Full Text] [PDF]

				C. J Field and P. D Schley Evidence for potential mechanisms for the effect of conjugated linoleic acid on tumor metabolism and immune function: lessons from n-3 fatty acids Am. J. Clinical Nutrition, June 1, 2004; 79(6): 1190S - 1198S. [Abstract] [Full Text] [PDF]

				M. Q. Kemp, B. D. Jeffy, and D. F. Romagnolo Conjugated Linoleic Acid Inhibits Cell Proliferation through a p53-Dependent Mechanism: Effects on the Expression of G1-Restriction Points in Breast and Colon Cancer Cells J. Nutr., November 1, 2003; 133(11): 3670 - 3677. [Abstract] [Full Text] [PDF]

				M. F. Insua, A. Garelli, N. P. Rotstein, O. L. German, A. Arias, and L. E. Politi Cell Cycle Regulation in Retinal Progenitors by Glia-Derived Neurotrophic Factor and Docosahexaenoic Acid Invest. Ophthalmol. Vis. Sci., May 1, 2003; 44(5): 2235 - 2244. [Abstract] [Full Text] [PDF]

				M.-F. Demierre and L. Nathanson Chemoprevention of Melanoma: An Unexplored Strategy J. Clin. Oncol., January 1, 2003; 21(1): 158 - 165. [Abstract] [Full Text] [PDF]

				A. P. Simopoulos The Mediterranean Diets: What Is So Special about the Diet of Greece? The Scientific Evidence J. Nutr., November 1, 2001; 131(11): 3065S - 3073. [Abstract] [Full Text] [PDF]